Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Reporter Scaffolds for Clinically Relevant Cell Transplantation Studies.

Bolger M, Groynom R, Bogie K, Lavik E.

Ann Biomed Eng. 2019 Nov 4. doi: 10.1007/s10439-019-02393-z. [Epub ahead of print]

PMID:
31686310
2.

Biomimetic Strategies To Treat Traumatic Brain Injury by Leveraging Fibrinogen.

Brown AC, Lavik E, Stabenfeldt SE.

Bioconjug Chem. 2019 Jul 17;30(7):1951-1956. doi: 10.1021/acs.bioconjchem.9b00360. Epub 2019 Jul 5.

PMID:
31246419
3.

Hemostatic nanoparticles increase survival, mitigate neuropathology and alleviate anxiety in a rodent blast trauma model.

Hubbard WB, Lashof-Sullivan M, Greenberg S, Norris C, Eck J, Lavik E, VandeVord P.

Sci Rep. 2018 Jul 13;8(1):10622. doi: 10.1038/s41598-018-28848-2.

4.

Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma.

Onwukwe C, Maisha N, Holland M, Varley M, Groynom R, Hickman D, Uppal N, Shoffstall A, Ustin J, Lavik E.

Bioconjug Chem. 2018 Jul 18;29(7):2436-2447. doi: 10.1021/acs.bioconjchem.8b00335. Epub 2018 Jul 9.

5.

The Chemistry of Lyophilized Blood Products.

Fernandez-Moure J, Maisha N, Lavik EB, Cannon JW.

Bioconjug Chem. 2018 Jul 18;29(7):2150-2160. doi: 10.1021/acs.bioconjchem.8b00271. Epub 2018 Jun 13. Review.

6.

Distinguishing the Unique Neuropathological Profile of Blast Polytrauma.

Hubbard WB, Greenberg S, Norris C, Eck J, Lavik E, VandeVord P.

Oxid Med Cell Longev. 2017;2017:5175249. doi: 10.1155/2017/5175249. Epub 2017 Mar 23.

7.

Science in a Global Community.

van Hest J, Lavik EB, Smith BD, Zheng G, Rotello VM.

Bioconjug Chem. 2017 Feb 15;28(2):279-281. doi: 10.1021/acs.bioconjchem.7b00058. No abstract available.

PMID:
28196421
8.

Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.

Lavik E, Kuehn MH, Shoffstall AJ, Atkins K, Dumitrescu AV, Kwon YH.

J Ocul Pharmacol Ther. 2016 Dec;32(10):642-649. Epub 2016 Nov 11.

9.

Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C.

Lashof-Sullivan M, Holland M, Groynom R, Campbell D, Shoffstall A, Lavik E.

ACS Biomater Sci Eng. 2016 Mar 14;2(3):385-392. Epub 2016 Jan 18.

10.

Materials design at the interface of nanoparticles and innate immunity.

Szeto GL, Lavik EB.

J Mater Chem B. 2016 Mar 7;4(9):1610-1618. Epub 2016 Jan 29. No abstract available.

11.

Editorial.

van Hest J, Lavik EB, Smith BD, Zheng G, Rotello V.

Bioconjug Chem. 2016 Jan 20;27(1):1-2. doi: 10.1021/acs.bioconjchem.6b00001. No abstract available.

PMID:
26786716
12.

Controlled release of photoswitch drugs by degradable polymer microspheres.

Groynom R, Shoffstall E, Wu LS, Kramer RH, Lavik EB.

J Drug Target. 2015;23(7-8):710-5. doi: 10.3109/1061186X.2015.1060978.

13.

A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway.

Tsuneki M, Hardee S, Michaud M, Morotti R, Lavik E, Madri JA.

Lab Invest. 2015 Jul;95(7):765-80. doi: 10.1038/labinvest.2015.61. Epub 2015 May 11.

14.

Steroid-Loaded Hemostatic Nanoparticles Combat Lung Injury after Blast Trauma.

Hubbard WB, Lashof-Sullivan MM, Lavik EB, VandeVord PJ.

ACS Macro Lett. 2015 Apr 21;4(4):387-391. Epub 2015 Mar 23.

15.

Editorial.

van Hest J, Lavik EB, Smith BD, Zheng G, Rotello VM.

Bioconjug Chem. 2015 Feb 18;26(2):163-5. doi: 10.1021/acs.bioconjchem.5b00002. Epub 2015 Jan 15. No abstract available.

PMID:
25588645
16.

Examining lethality risk for rodent studies of primary blast lung injury.

Hubbard WB, Hall C, Siva Sai Suijith Sajja V, Lavik E, VandeVord P.

Biomed Sci Instrum. 2014;50:92-9.

17.

Olfactory ensheathing cells promote differentiation of neural stem cells and robust neurite extension.

Sethi R, Sethi R, Redmond A, Lavik E.

Stem Cell Rev Rep. 2014 Dec;10(6):772-85. doi: 10.1007/s12015-014-9539-7. Review.

18.

Intravenously administered nanoparticles increase survival following blast trauma.

Lashof-Sullivan MM, Shoffstall E, Atkins KT, Keane N, Bir C, VandeVord P, Lavik EB.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10293-8. doi: 10.1073/pnas.1406979111. Epub 2014 Jun 30.

19.

Intravenous hemostats: challenges in translation to patients.

Lashof-Sullivan M, Shoffstall A, Lavik E.

Nanoscale. 2013 Nov 21;5(22):10719-28. doi: 10.1039/c3nr03595f. Epub 2013 Oct 2. Review.

20.

Tuning ligand density on intravenous hemostatic nanoparticles dramatically increases survival following blunt trauma.

Shoffstall AJ, Everhart LM, Varley ME, Soehnlen ES, Shick AM, Ustin JS, Lavik EB.

Biomacromolecules. 2013 Aug 12;14(8):2790-7. doi: 10.1021/bm400619v. Epub 2013 Jul 24.

21.

A tunable synthetic hydrogel system for culture of retinal ganglion cells and amacrine cells.

Hertz J, Robinson R, Valenzuela DA, Lavik EB, Goldberg JL.

Acta Biomater. 2013 Aug;9(8):7622-9. doi: 10.1016/j.actbio.2013.04.048. Epub 2013 May 3.

22.

Tissue engineering the retinal ganglion cell nerve fiber layer.

Kador KE, Montero RB, Venugopalan P, Hertz J, Zindell AN, Valenzuela DA, Uddin MS, Lavik EB, Muller KJ, Andreopoulos FM, Goldberg JL.

Biomaterials. 2013 Jun;34(17):4242-50. doi: 10.1016/j.biomaterials.2013.02.027. Epub 2013 Mar 11.

23.

Short term interactions with long term consequences: modulation of chimeric vessels by neural progenitors.

Williams C, Rauch MF, Michaud M, Robinson R, Xu H, Madri J, Lavik E.

PLoS One. 2012;7(12):e53208. doi: 10.1371/journal.pone.0053208. Epub 2012 Dec 27.

24.

Intravenous hemostatic nanoparticles increase survival following blunt trauma injury.

Shoffstall AJ, Atkins KT, Groynom RE, Varley ME, Everhart LM, Lashof-Sullivan MM, Martyn-Dow B, Butler RS, Ustin JS, Lavik EB.

Biomacromolecules. 2012 Nov 12;13(11):3850-7. doi: 10.1021/bm3013023. Epub 2012 Oct 8.

25.

Medicine. Leveraging shear stress to bust clots with nanoparticles.

Lavik E, Ustin J.

Science. 2012 Aug 10;337(6095):658-9. doi: 10.1126/science.1227097. No abstract available.

PMID:
22879494
26.

Bioengineering approaches to nervous system repair.

Lavik E.

Neurosci Lett. 2012 Jun 25;519(2):85-6. doi: 10.1016/j.neulet.2012.06.001. No abstract available.

PMID:
22704082
27.

Engineering therapies in the CNS: what works and what can be translated.

Shoffstall AJ, Taylor DM, Lavik EB.

Neurosci Lett. 2012 Jun 25;519(2):147-54. doi: 10.1016/j.neulet.2012.01.058. Epub 2012 Feb 4. Review.

28.

Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery.

Robinson R, Viviano SR, Criscione JM, Williams CA, Jun L, Tsai JC, Lavik EB.

ACS Nano. 2011 Jun 28;5(6):4392-400. doi: 10.1021/nn103146p. Epub 2011 Jun 9.

29.

The role of nanomaterials in translational medicine.

Lavik E, von Recum H.

ACS Nano. 2011 May 24;5(5):3419-24. doi: 10.1021/nn201371a.

30.

Novel drug delivery systems for glaucoma.

Lavik E, Kuehn MH, Kwon YH.

Eye (Lond). 2011 May;25(5):578-86. doi: 10.1038/eye.2011.82. Epub 2011 Apr 8. Review.

31.

Intravenous hemostat: nanotechnology to halt bleeding.

Bertram JP, Williams CA, Robinson R, Segal SS, Flynn NT, Lavik EB.

Sci Transl Med. 2009 Dec 16;1(11):11ra22. doi: 10.1126/scitranslmed.3000397.

32.

Exogenous modulation of intrinsic optic nerve neuroprotective activity.

Grozdanic SD, Lazic T, Kuehn MH, Harper MM, Kardon RH, Kwon YH, Lavik EB, Sakaguchi DS.

Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1105-16. doi: 10.1007/s00417-010-1336-7. Epub 2010 Mar 13.

33.

A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space.

Hynes SR, Lavik EB.

Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):763-78. doi: 10.1007/s00417-009-1263-7. Epub 2010 Feb 19. Review.

PMID:
20169358
34.

New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres.

Robinson R, Bertram JP, Reiter JL, Lavik EB.

J Microencapsul. 2010 May;27(3):263-71. doi: 10.3109/02652040903131285.

35.

Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF.

Bertram JP, Rauch MF, Chang K, Lavik EB.

Pharm Res. 2010 Jan;27(1):82-91. doi: 10.1007/s11095-009-0009-x. Epub 2009 Nov 17.

PMID:
19921405
36.

Engineering the CNS stem cell microenvironment.

Williams CA, Lavik EB.

Regen Med. 2009 Nov;4(6):865-77. doi: 10.2217/rme.09.62. Review.

37.

Delayed administration of glial cell line-derived neurotrophic factor (GDNF) protects retinal ganglion cells in a pig model of acute retinal ischemia.

Kyhn MV, Klassen H, Johansson UE, Warfvinge K, Lavik E, Kiilgaard JF, Prause JU, Scherfig E, Young M, la Cour M.

Exp Eye Res. 2009 Dec;89(6):1012-20. doi: 10.1016/j.exer.2009.08.014. Epub 2009 Sep 4.

PMID:
19735654
38.

Functionalized poly(lactic-co-glycolic acid) enhances drug delivery and provides chemical moieties for surface engineering while preserving biocompatibility.

Bertram JP, Jay SM, Hynes SR, Robinson R, Criscione JM, Lavik EB.

Acta Biomater. 2009 Oct;5(8):2860-71. doi: 10.1016/j.actbio.2009.04.012. Epub 2009 May 4.

39.

Engineering angiogenesis following spinal cord injury: a coculture of neural progenitor and endothelial cells in a degradable polymer implant leads to an increase in vessel density and formation of the blood-spinal cord barrier.

Rauch MF, Hynes SR, Bertram J, Redmond A, Robinson R, Williams C, Xu H, Madri JA, Lavik EB.

Eur J Neurosci. 2009 Jan;29(1):132-45. doi: 10.1111/j.1460-9568.2008.06567.x.

40.

Co-culture of primary neural progenitor and endothelial cells in a macroporous gel promotes stable vascular networks in vivo.

Rauch MF, Michaud M, Xu H, Madri JA, Lavik EB.

J Biomater Sci Polym Ed. 2008;19(11):1469-85. doi: 10.1163/156856208786140409.

PMID:
18973724
41.

Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months.

Bertram JP, Saluja SS, McKain J, Lavik EB.

J Microencapsul. 2009 Feb;26(1):18-26. doi: 10.1080/02652040802095250. Erratum in: J Microencapsul. 2009 Feb;26(1):26.

PMID:
18465288
42.

A library of tunable poly(ethylene glycol)/poly(L-lysine) hydrogels to investigate the material cues that influence neural stem cell differentiation.

Hynes SR, Rauch MF, Bertram JP, Lavik EB.

J Biomed Mater Res A. 2009 May;89(2):499-509. doi: 10.1002/jbm.a.31987.

PMID:
18435406
43.

Poly(lactic-co-glycolic acid) nanospheres and microspheres for short- and long-term delivery of bioactive ciliary neurotrophic factor.

Nkansah MK, Tzeng SY, Holdt AM, Lavik EB.

Biotechnol Bioeng. 2008 Aug 1;100(5):1010-9. doi: 10.1002/bit.21822.

PMID:
18431801
44.

Photopolymerized poly(ethylene glycol)/poly(L-lysine) hydrogels for the delivery of neural progenitor cells.

Royce Hynes S, McGregor LM, Ford Rauch M, Lavik EB.

J Biomater Sci Polym Ed. 2007;18(8):1017-30.

PMID:
17705996
45.

Creating an immune-privileged site using retinal progenitor cells and biodegradable polymers.

Ng TF, Lavik E, Keino H, Taylor AW, Langer RS, Young MJ.

Stem Cells. 2007 Jun;25(6):1552-9.

46.

CNTF promotes the survival and differentiation of adult spinal cord-derived oligodendrocyte precursor cells in vitro but fails to promote remyelination in vivo.

Talbott JF, Cao Q, Bertram J, Nkansah M, Benton RL, Lavik E, Whittemore SR.

Exp Neurol. 2007 Mar;204(1):485-9. Epub 2006 Dec 20.

47.

Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres.

Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ.

J Pharm Sci. 2007 Mar;96(3):558-68.

PMID:
17177208
48.
49.

A macroporous hydrogel for the coculture of neural progenitor and endothelial cells to form functional vascular networks in vivo.

Ford MC, Bertram JP, Hynes SR, Michaud M, Li Q, Young M, Segal SS, Madri JA, Lavik EB.

Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2512-7. Epub 2006 Feb 10.

50.

Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells.

Tomita M, Lavik E, Klassen H, Zahir T, Langer R, Young MJ.

Stem Cells. 2005 Nov-Dec;23(10):1579-88.

Supplemental Content

Support Center